Stephanie Graff Highlights ASCENT-04 Results Supporting SG plus Pembrolizumab in TNBC
Stephanie Graff, Director of Breast Oncology at Brown University Health and an Associate Professor of Medicine at Brown University’s Legorreta Cancer Center, shared a post on X:
“ASCENT04 changes practice w/ improved mPFS 11.2 vs. 7.8 mos; 12 mon PFS 48 vs 33 mos w/ impressive tail suggesting potential for group with durable sustained response; adverse events were not additive. Bonus points for cross over design.”
Harold J. Burstein, Breast cancer specialist and professor at Dana-Farber Cancer Institute, reshared the post on X, adding:
“I think that’s probably correct. In 2nd line, SC > chemo.
By the additive property, we now see that SG + pembro > chemo + pembro. Control arm performed as in KN355 chemo/pembro.
Seems like a good option, and supports growing idea that SG might be preferred in TNBC.”
More posts featuring Stephanie Graff.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023